Literature DB >> 2393270

In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.

T Kojima1, M Inoue, S Mitsuhashi.   

Abstract

Eighty-nine clinical isolates of Staphylococcus aureus that were resistant to both ciprofloxacin (MIC, greater than or equal to 3.13 micrograms/ml) and methicillin (MIC, greater than or equal to 12.5 micrograms/ml) were divided into two groups with respect to their susceptibilities to AT-4140. Most isolates that were moderately resistant to ciprofloxacin (MICs, 3.13 to 12.5 micrograms/ml) or ofloxacin (MICs, 0.78 to 6.25 micrograms/ml) were susceptible to AT-4140 (MICs, 0.05 to 0.2 microgram/ml). Most isolates that were highly resistant to ciprofloxacin (MIC, greater than or equal to 25 micrograms/ml) or ofloxacin (MIC, greater than or equal to 12.5 micrograms/ml) were resistant to AT-4140 (MICs, 3.13 to 25 micrograms/ml). The appearance of spontaneous single-step, quinolone-resistant mutants of S. aureus P-20, a methicillin-resistant isolate, was more frequent than was that of S. aureus 209P JC-1, a susceptible laboratory strain. Spontaneous single-step, quinolone-resistant mutants of P-20 were not selected by AT-4140, and those selected by existing fluoroquinolones were susceptible to AT-4140. Spontaneous double-step, quinolone-resistant mutants of P-20 were selected by various fluoroquinolones. All second-step mutants selected by AT-4140 or ofloxacin from P-20-C, a spontaneous single-step mutant of P-20 selected by ciprofloxacin, were resistant to all the quinolones. All second-step mutants selected by nonfloxacin were resistant to all existing fluoroquinolones but were less resistant to AT-4140. There was a close resemblance between the resistance profiles of spontaneous quinolone-resistant mutants and those of clinically isolated quinolone- and methicillin-resistant S. aureus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2393270      PMCID: PMC171769          DOI: 10.1128/AAC.34.6.1123

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli.

Authors:  S Nakamura; M Nakamura; T Kojima; H Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.

Authors:  S M Smith; R H Eng; F Tecson-Tumang
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

3.  New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

Authors:  J Yamagishi; Y Furutani; S Inoue; T Ohue; S Nakamura; M Shimizu
Journal:  J Bacteriol       Date:  1981-11       Impact factor: 3.490

4.  Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus.

Authors:  B J Hartman; A Tomasz
Journal:  J Bacteriol       Date:  1984-05       Impact factor: 3.490

5.  In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.

Authors:  S Nakamura; A Minami; K Nakata; N Kurobe; K Kouno; Y Sakaguchi; S Kashimoto; H Yoshida; T Kojima; T Ohue
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  In vitro activity of AT-4140 against clinical bacterial isolates.

Authors:  T Kojima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

8.  Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus.

Authors:  S M Smith; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

9.  Occurrence of a beta-lactam-inducible penicillin-binding protein in methicillin-resistant staphylococci.

Authors:  K Ubukata; N Yamashita; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

View more
  19 in total

1.  Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

2.  Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin.

Authors:  M E Evans; W B Titlow
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

3.  Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.

Authors:  J Okuda; S Okamoto; M Takahata; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  Pharmacokinetics of sparfloxacin in patients with renal impairment.

Authors:  J P Fillastre; G Montay; R Bruno; I Etienne; M Dhib; N Vivier; Y Le Roux; C Guimart; G Gay; D Schott
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

5.  In vitro activity of T-3761, a new fluoroquinolone.

Authors:  T Muratani; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

6.  In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia.

Authors:  E Azoulay-Dupuis; E Vallee; B Veber; J P Bedos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.

Authors:  Y Fukuoka; Y Ikeda; Y Yamashiro; M Takahata; Y Todo; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells.

Authors:  I García; A Pascual; M C Guzman; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

10.  Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci.

Authors:  A G Miranda; A R Wanger; K V Singh; B E Murray
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.